Original Research
Long-Term Valbenazine for Tardive Dyskinesia
Valbenazine, a VMAT2 inhibitor, is approved for the treatment of tardive dyskinesia. However, its long-term safety and efficacy have not been reported. This extension of the KINECT 3 study...
